• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    MPO's 2023 Medical Device Industry Year in Review

    The Beat Goes On in the Cardiovascular Device Market

    Medical Manufacturers Gain Support from 3D Printing

    The Intelligent Tools Medical Device Manufacturers Already Own

    MPO's 2023 Medtech Supply Chain Survey
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    New Wearable Sends Vital Signs 15 Miles Without Cell Service

    Keystone Medical Technologies Opens Manufacturing Facility in Chattanooga, TN

    Withings Unveils ScanWatch Nova

    DiagnaMed Debuts New Healthcare Provider Network Program

    Dinsmore Becomes HP Digital Manufacturing Partner
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    MPO's 2023 Medical Device Industry Year in Review

    The Beat Goes On in the Cardiovascular Device Market

    Medical Manufacturers Gain Support from 3D Printing

    The Intelligent Tools Medical Device Manufacturers Already Own

    MPO's 2023 Medtech Supply Chain Survey
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    A Peek Into the 2028 MPO Summit

    Retail Healthcare Disruptors and Medical Devices

    Six Developments Your Talent Strategy Should Prepare for in 2024

    The Power and Paradox of Never

    Navigating the Q-Sub Program: How Experienced Lab Partners Can Help Streamline Regulatory Submission
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Qosina Corp.

    Johari Digital Healthcare Ltd.

    Arthur G Russell Company, The

    Providence Enterprise USA Inc.

    LEMO USA Inc.
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Telemedicine for Neurology: 5 Benefits of Remote Management

    Machining 101: A Review of Machining Components with a Five-Axis System

    MedTech 2024: Top 5 Trends Shaping a Dynamic Industry

    Early Warning: A Q&A with Abbott's CMO of Heart Failure

    2023 in Review: Medtech's Mega-M&A Is MIA
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Qosina Corp.

    Johari Digital Healthcare Ltd.

    Arthur G Russell Company, The

    Providence Enterprise USA Inc.

    LEMO USA Inc.
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    U.S. Premarket Submissions: Understanding the Necessary Regulatory Controls

    Successfully navigating the regulatory hoops becomes even more complicated depending on the market in which manufacturers hope to launch their product.

    U.S. Premarket Submissions: Understanding the Necessary Regulatory Controls
    Sandi Schaible and Dr. Sherry Parker, WuXi AppTec Medical Device Testing03.03.22
    Perhaps the most exciting and rewarding part of medical device manufacturing is bringing to market an effective, innovative, and safe healthcare solution for patients. Getting to that point, however, is no easy feat. Understanding the regulatory controls and premarketing pathways is critical—and challenging. Successfully navigating the regulatory hoops becomes even more complicated depending on the market in which manufacturers hope to launch their product.

    The first in a two-part series on premarket submissions, this article highlights the critical steps necessary to proceed with U.S. premarket submissions.

    The 1938 U.S. Food, Drug & Cosmetics Act is the legal framework that authorizes the U.S. Food and Drug Administration (FDA) to regulate medical device manufacturing and use. Today's FDA adopts a risk-based approach to medical devices and, regarding safety data, expects a full biological evaluation of devices, including chemical characterization data, a toxicological risk assessment, and biological data in a comprehensive weight of evidence review.

    The FDA's focus on risk is important to remember because a crucial step in any premarket submission is classifying a device according to its risk level.

    Medical Device Classification
    The FDA has classified around 1,700 medical devices into 16 specialty areas—also called panels—and organized them in the Code of Federal Regulations (CFR). Classification depends on a device's intended use and its indications for use. For example, a scalpel is used to cut tissue, but its indications for use may be more specialized. Scalpels designed to cut delicate corneal tissue will include a different indication than those used to cut thick dermal tissue. In this case, the different indications for these scalpels may impact their classification. Indications for use are most often found in the device's labeling.

    Regardless of classification, a device's risk to patients and users determines the risk level and regulatory panel to which it is assigned. Class I devices pose the lowest risk; Class III includes the most significant potential risks. A device's class dictates the premarket effort required to obtain regulatory clearance.

    According to the FDA, "Most Class I devices are exempt from premarket notification 510(k); most Class II devices require premarket notification 510(k); and most Class III devices require premarket approval."

    Most medical devices obtain U.S. regulatory clearance via premarket notification [510(k) submission]. This submission must show the device is substantially equivalent (SE) to a predicate device (one with an identical intended use that is sold in the U.S.). Most manufacturers choose a product recently cleared under 510(k) guidelines as the predicate device, but any appropriate legally marketed device can be used.

    The FDA considers a device substantially equivalent if, compared to a predicate, it:
    • has an identical intended use to the predicate; and
    • has identical technological characteristics to the predicate; or
    • has an identical intended use to the predicate; and
    • has different technological characteristics but has the same safety and effectiveness assurances; and
    • information submitted to FDA demonstrates the device is as safe and effective as a legally marketed device.
    Devices requiring a 501(k) submission cannot be distributed commercially until the manufacturer receives a letter of SE from the FDA. Non-SE devices require a premarket approval (PMA) application to obtain sales clearance.

    Class I and specific Class II devices are considered exempt and do not require a PMA to be market-ready. Class III devices carry the highest risk and generally pose a significant risk of illness or injury. The PMA process can be more intricate, requiring about 20 percent of manufacturers to include clinical data in their 510(k) submissions. Class III devices that fail to meet PMA requirements are deemed "adulterated" and cannot be marketed.

    Manufacturers unsure about their device's classification can use the FDA's classification database to find the regulation number corresponding to its classification. Manufacturers can also search by device panel (medical specialty) to identify their device and any pertinent regulatory specifics.

    When No Predicate Device Exists
    The existence of a predicate device makes risk evaluation and premarket submissions relatively straightforward. However, a "De Novo request" is a marketing pathway for novel medical devices that cannot claim a predicate device but can reasonably assure safety and effectiveness. A De Novo request is a risk-based classification that applies only to Class I or II devices. Manufacturers should make De Novo requests for:
    • Devices deemed non-SE in response to a 510(k) application
    • Devices wherein no predicate product exists in which to base an SE determination
    The FDA recommends manufacturers submit a pre-submission evaluation with De Novo applications so the agency can provide feedback or offer specific guidance before an official premarket submission.

    COVID-19 also changed the medical device regulatory pathway. The FDA is charged with protecting the public against biological, chemical, radiological, or nuclear threats; consequently, it granted emergency use authorization (EUA) to new medical devices designed to battle SARS-CoV-2.

    An EUA allows the FDA to authorize unapproved devices or unapproved uses of approved devices in emergencies. Medical products that help diagnose, treat, or prevent serious or life-threatening diseases or conditions can be fast-tracked even if no predicate device exists.

    Marketing Pathways for Humanitarian Devices
    Class III medical devices that treat rare diseases or conditions may qualify for humanitarian use designation (HUD). To obtain clearance, manufacturers must apply for the designation through the FDA's Office of Orphan Products Development (OOPD).

    The OOPD works with medical researchers, professional organizations, academic institutions, governments, and patient groups to fast-track submissions for devices, drugs, biologics, or medical foods that promise to treat, prevent, or diagnose rare conditions.

    A 2016 amendment to the HUD designation defines a "rare" disease or condition as one that affects no more than 8,000 U.S. individuals annually. Manufacturers applying for a HUD must be able to justify the patient need for their device and its indications for use.

    Combination Product Complexity
    An exception to the aforementioned guidance applies to combination products. The complexity and uniqueness of these devices requires additional guidance from the FDA's Office of Combination Products (OCP).

    Combination products contain a combination of drugs, devices, and biologics that, individually, would be regulated by one of three FDA centers: the Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), or Center for Devices and Radiological Health (CDRH).

    A combination product's primary mode of action (PMOA) may help manufacturers determine which regulatory center has primary jurisdiction and is ultimately responsible for its review. If the PMOA falls to the product’s device element, the CDRH is the principal reviewer. If a drug or biologic is responsible for the PMOA, the CBER or CDER is in charge. 

    If a device has two independent modes of action, and neither is subordinate to the other, the FDA has an algorithm for determining center assignment. Together, the product category and PMOA determine how to engage the appropriate regulatory center.

    Final Preparations Before Premarket Submission
    Once a manufacturer appropriately classifies a device and determines the correct regulatory review process, there are administrative details that should not be overlooked.
    • User fees: Certain applications have user fees. Manufacturers that qualify as "small businesses" or those seeking HUD are eligible for substantial fee reductions.
    • Digital copies: The FDA requires all premarket submissions to include digital versions of all documents. CDs, DVDs, or flash drives fulfill this requirement.

    A Final Recommendation
    Introducing a new medical device to the U.S. market is not easy but the process is well-documented and the FDA provides guidance. In fact, regulators will conduct an initial administrative review of premarket submissions to ensure the submission is complete and the review process runs smoothly.

    Yet compiling the necessary documentation for premarket submissions can be daunting and time-consuming. Device manufacturers new to the U.S. market or those introducing novel or humanitarian devices cannot risk missing a step or overlooking a critical part of the process. An experienced lab testing partner can ensure manufacturers are on the right track and improve their chances of regulatory success. 


    Sandi Schaible is the senior director of analytical chemistry and regulatory toxicology at WuXi AppTec Medical Device Testing, specializing in extractables and leachables studies. She is a U.S. delegate and international delegate for ISO 10993 part 18 in chemical characterization, and a U.S. delegate for ISO 10993 part 13 and the particulates committee.

    Dr. Sherry Parker has over 20 years of toxicology and medical device experience and is an expert in biological evaluation of medical devices and combination products. Dr. Parker provides manufacturers with guidance on global regulatory and technical requirements and testing program design. In May 2019, Dr. Parker was appointed to a three-year term as co-chair of the Biological Evaluation Committee. She is an internationally recognized ISO expert and a U.S. delegate for TC 194, the technical committee for ISO 10993, and is a past president of the Medical Device and Combination Products Specialty Section of the Society of Toxicology.
      Loading, Please Wait..

      Breaking News
      • New Wearable Sends Vital Signs 15 Miles Without Cell Service
      • Keystone Medical Technologies Opens Manufacturing Facility in Chattanooga, TN
      • Withings Unveils ScanWatch Nova
      • DiagnaMed Debuts New Healthcare Provider Network Program
      • Dinsmore Becomes HP Digital Manufacturing Partner
      View Breaking News >
      CURRENT ISSUE

      November 2023

      • MPO's 2023 Medical Device Industry Year in Review
      • The Beat Goes On in the Cardiovascular Device Market
      • Medical Manufacturers Gain Support from 3D Printing
      • The Intelligent Tools Medical Device Manufacturers Already Own
      • View More >

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Lion’s Mane Extract Linked to Better Cognitive Performance, Subjective Stress
      NutraShure Introduces SA3X as Exclusive US Supplier
      NPA Lawsuit Claims New York Age Restriction on Supplements is Unconstitutional
      Coatings World

      Latest Breaking News From Coatings World

      Albert Extends Coverage of Transformational Regulatory Automation Capabilities to China and Taiwan
      BCF Urges Government to Recognize Importance of Coatings Industry
      AkzoNobel Graduates First Engineers from Training Program
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      New Wearable Sends Vital Signs 15 Miles Without Cell Service
      Keystone Medical Technologies Opens Manufacturing Facility in Chattanooga, TN
      Withings Unveils ScanWatch Nova
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Abzena, ProteoNic Partner to Offer Enhanced CHO Cell Line Platform
      AQEMIA Inks $140M Small Molecule Deal with Sanofi
      Hoth Therapeutics, WuXi STA Complete Manufacturing of HT-KIT
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      The Honest Company Expands Partnership with Tinuiti
      DedCool Introduces New Sephora-Exclusive Fragrance
      MAC Cosmetics Brings Back Fizzy Feels Lip Balm
      Happi

      Latest Breaking News From Happi

      Naples Soap Company Reports Record-High Sales During Thanksgiving Weekend 2023
      Glo30 Welcomes Artemis Benedetti as New Director of Franchise Operations
      Trace Minerals Taps Charles Walkley as Chief Operating Officer
      Ink World

      Latest Breaking News From Ink World

      Avient Attains ACC Responsible Care 14001 Global Certification
      BCF Urges Government to Recognize Importance of Ink and Coatings
      CCL Industries Names Claude Tessier to Board of Directors
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      All4Labels Group acquires Uniflexo
      Rosas Maschinenbau introduces new RFID label converting line
      Lecta unveils new functional Metalvac papers
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      INDA Seeking Abstracts for World of Wipes International Conference
      Monadnock Introduces New Generation of Veils
      G-P Invests in Oregon Facility
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Sonex Health Raises $40 Million in Series B Financing
      Precision Medical Technologies Rebrands
      Nalu SCS System Shows 75% Pain Reduction in U.S. Study
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Four Scientists Receive Battelle Distinguished Inventor Recognition
      Applied Materials and CEA-Leti Unveil Joint Lab for Specialty Chip Markets
      Sandvik Manufacturing Partners with RISE

      Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login